New scan could reveal hidden kidney cancer

NCT ID NCT07671417

Not yet recruiting Diagnosis Sponsor: RayzeBio, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This early-phase study tests a new imaging agent called RYZ512 in 10 people with advanced clear cell kidney cancer that has spread. The agent is designed to attach to a protein (CAIX) found on these cancer cells, making them show up on scans. The goal is to see if it is safe and how it spreads through the body, not to treat the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RYZ512 (imaging agent)
What this could lead to: If successful, this could lead to a better way to see where kidney cancer has spread, helping doctors plan treatment.
What could go wrong: This is a very early, small study (10 people) focused on imaging, not treatment. The tracer may not work as hoped or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CLEAR CELL RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

clear cell renal carcinoma Clear-cell metastatic renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CLEAR CELL RENAL CELL CARCINOMA

Contacts and locations

Locations

Research Facility

Christchurch, New Zealand

More trials for these conditions

Other studies related to the condition(s) this trial covers.